We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Vertex Pharmaceuticals Inc | NASDAQ:VRTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 7.74 | 1.92% | 410.24 | 409.00 | 412.00 | 415.67 | 394.0323 | 406.42 | 1,613,842 | 23:53:43 |
From May 2019 to May 2024
By Colin Kellaher
Vertex Pharmaceuticals Inc. on Thursday said it entered a research collaboration and licensing agreement with privately held Obsidian Therapeutics aimed at finding new therapies that regulate gene editing for the treatment of serious diseases.
Boston drug maker Vertex said Obsidian will use its cytoDRiVE technology to develop therapy candidates, while Vertex will have the exclusive option to license worldwide rights to the candidates, with responsibility for further development and commercialization.
Vertex said it will pay Obsidian up to $75 million in upfront payments and research milestones during the research term, including an equity investment in Obsidian.
The company said Obsidian is eligible to receive up to $1.3 billion in potential research, development, regulatory, and commercial milestone payments across up to five potential programs, along with royalties on sales of any products resulting from the collaboration.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 22, 2021 08:38 ET (12:38 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Vertex Pharmaceuticals Chart |
1 Month Vertex Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
